Open Journal Systems

Analysis of Clinical Progress of Trudezumab in the Treatment of HER2+ Breast Cancer

Baoyan Liang (Liaoning Cancer Hospital and Institute, Shenyang, China)
Shasha Wang (Fleming Research Center of Life Sciences, Singapore)

Abstract


Breast cancer is a malignant tumor disease that endangers women's health, the morbidity is increasing year by year. HER2+ breast cancer has been the focus of clinical research because of its high invasiveness and poor prognosis. Trastuzumab in clinical application of HER2+ mammary cancer has greatly improved the prognosis. However, drug resistance and adverse reactions after treatment have effects on the large area promotion of trastuzumab, therefore, the addition of new anti-HER2 drugs to the existing standard therapy has become a hot topic in clinical research at the present stage. This article reviews the clinical progress of the trastuzumab therapy on HER2+ breast cancer from the aspects of combined chemotherapy, combined endocrine therapy and combined with other targeted therapy drugs.


Keywords


Trastuzumab; HER2+ breast cancer; Targeted therapy

Full Text:

PDF

References


Wang Lifeng, Ma Yanfei, Li Xiaofeng. Clinical efficacy of trastuzumab and lapatinib in the treatment of early HER2 overexpression breast cancer [J]. International Journal of Surgery,2019, 46(5):321-325.

Xing Hanfei, Han Chao. Trastuzumab combined with paclitaxel neoadjuvant chemotherapy in the treatment of HER2-positive advanced local breast cancer [J]. Medical Theory & Practice,2019,32 (10):1535-1537.

Liu Changqing. Trastuzumab combined with docetaxel in the treatment of HER2+ metastatic breast cancer [J]. Current Medicine, 2019,25(9):79-81.

Han Yiqun, Fan Ying, Chen Shanghua, et al. J Clin Therapeutics,2019,17(6):71-75. (in Chinese with English abstract) [J]. J Clin Therapeutics,2019,17(6):71-75.

Wang Yan. Clinical study of trastuzumab combined with PC weekly chemotherapy in patients with HER2-positive advanced breast cancer [J]. Clinical Practice of Integrated Traditional Chinese and Western Medicine,2019,19(3): 47-49.

Yang Yanfang. Advances in the treatment of HER2-positive breast cancer [J]. Chinese Journal of Cancer Biotherapy,2018,25(11): 120-1204.

Zhang Wenjing, Song Bing. Advances in molecular targeted therapy for breast cancer with positive HER-2 [J]. Journal of Medical Informatics,2018,31(24):42-47.

Yin Ziyi, Zhang Tie, Qu Gengbao. Efficacy evaluation of TP regimen combined with trastuzumab in the treatment of human epidermal growth factor receptor 2-positive breast cancer [J]. Cancer Progress,2019,17(12): 1391-1394.

Dong Ke, Gao Haidong. Research progress in clinical application of molecular targeted drugs for HER2-positive breast cancer [J]. Advances in Modern General Surgery in China,2018,21(5):373-375.

Wang Chunhui, Li Jing, Wu Wei, et al. Cardiac safety evaluation of trastuzumab in patients with HER2-positive tumor [J]. Journal of Adverse Drug Reactions,2019,21(4):265-272.



DOI: http://dx.doi.org/10.30564/amor.v6i4.277

Refbacks

  • There are currently no refbacks.


Copyright (c) 2020 Baoyan Liang, Shasha Wang

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.